3D-Printed eye patch could save sight without a donor

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age over 18 years. 2. Patients who, after receiving detailed information about the design, purpose, risks, and implications of the study, and about their right to withdraw at any time without repercussions, give their informed written consent. 3. Confirmed diagnosis of severe corneal melting. 4. Absence of response to conventional non-surgical treatments, which must include: * Intensive antibiotic, antifungal, or antiviral treatment according to etiology. * Anti-inflammatory or immunomodulatory eye drops (such as corticosteroids, cyclosporine, tacrolimus). * Intensive lubrication and/or autologous serum. * Use of therapeutic contact lenses. * The patient must not have responded satisfactorily to these measures and must show progression or persistence of the ulcer, thinning, and structural risk. The absence of response is not defined by a specific number of treatments, but by the lack of clinical improvement or progression of the condition despite having received several of these measures appropriately. In particular, progression of the epithelial defect, worsening stromal thinning, or the appearance of signs of perforation risk will be considered an absence of response, which would justify surgical intervention. 5. If the patient has previously undergone surgical procedures or received other implants (such as amniotic membrane, conjunctival flap, or Tenon's graft), this will be included if there is documented clinical progression without sufficient functional or structural recovery, and provided that there are no surgical alternatives with documented superior efficacy in their specific situation. Exclusion Criteria: 1. Pregnancy or breastfeeding. 2. Refusal to participate in the study. 3. Presence of active eye infection. 4. Systemic diseases that may affect healing. 5. Known hypersensitivity to collagen compounds. 6. Any circumstance that, in the investigator's opinion, makes the patient's participation in the clinical research inadvisable.